Prime Medicine, Inc.
PRME · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $889 | $319 | $260 | $346 |
| - Cash | $71 | $54 | $92 | $182 |
| + Debt | $118 | $120 | $121 | $41 |
| Enterprise Value | $936 | $385 | $290 | $205 |
| Revenue | $1 | $1 | $1 | $2 |
| % Growth | 9.9% | -23.3% | -33.4% | – |
| Gross Profit | -$43 | -$1 | $1 | $2 |
| % Margin | -3,491% | -67.2% | 100% | 100% |
| EBITDA | -$49 | -$52 | -$51 | -$43 |
| % Margin | -3,975.6% | -4,620% | -3,486.4% | -1,947.1% |
| Net Income | -$51 | -$53 | -$52 | -$42 |
| % Margin | -4,129.1% | -4,716.7% | -3,568.8% | -1,936.6% |
| EPS Diluted | -0.32 | -0.407 | -0.397 | -0.357 |
| % Growth | 21.4% | -2.7% | -11.2% | – |
| Operating Cash Flow | -$35 | -$41 | -$49 | $16 |
| Capital Expenditures | -$0 | -$2 | -$2 | -$2 |
| Free Cash Flow | -$35 | -$43 | -$51 | $14 |